Advertisement

Topics

ISCT revises cell and gene therapy industry forecast following approval of Novartis’ Kymriah/CTL019

07:35 EDT 1 Sep 2017 | thePharmaLetter

The Canada-based International Society for Cellular Therapy (ISCT), the global professional society of…

Original Article: ISCT revises cell and gene therapy industry forecast following approval of Novartis’ Kymriah/CTL019

NEXT ARTICLE

More From BioPortfolio on "ISCT revises cell and gene therapy industry forecast following approval of Novartis’ Kymriah/CTL019"

Quick Search
Advertisement